Five-year overall survival (OS) and OS by baseline liver function from the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

被引：0
|
作者：
Kudo, M. [1 ]
Rimassa, L. [2 ]
Chan, S. L. [3 ]
Sangro, B. [4 ,5 ,6 ]
Lau, G. [7 ]
Breder, V. V. [8 ]
Varela, M. [9 ]
Crysler, O. V. [10 ]
Bouattour, M. [11 ]
Dao, V. T. [12 ]
Faccio, A. [13 ]
Furuse, J. [14 ]
Jeng, L-B. [15 ]
Kang, Y-K. [16 ]
Kelley, R. K. [17 ]
Paskow, M. J. [18 ]
Makowsky, M. [19 ]
Ran, D. [20 ]
Negro, A. [19 ]
Abou-Alfa, G. K. [21 ,22 ]
机构：
[1] Kindai Univ, Fac Med, Dept Gastroenterol & Hepatol, Osaka, Japan
[2] Humanitas Univ, Pieve Emanuele & Humanitas Canc Ctr, IRCCS Humanitas Res Hosp, Dept Biomed Sci, Milan, Italy
[3] Chinese Univ Hong Kong, State Key Lab Translat Oncol, Dept Clin Oncol, Sir Yue Kong Pao Ctr Canc, Hong Kong, Peoples R China
[4] Clin Univ Navarra, Liver Unit, Pamplona, Spain
[5] Clin Univ Navarra, HPB Oncol Area, Pamplona, Spain
[6] CIBEREHD, Pamplona, Spain
[7] Humanity & Hlth Med Grp, Humanity & Hlth Clin Trial Ctr, Hong Kong, Peoples R China
[8] NN Blokhin Natl Med Res Ctr Oncol, Dept Chemotherapy, Moscow, Russia
[9] Univ Oviedo, Liver Unit, Hosp Univ Cent Asturias, IUOPA,ISPA,FINBA, Oviedo, Spain
[10] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI USA
[11] Hop Beaujon, AP HP, Liver Canc Unit, Paris, France
[12] Natl Canc Hosp, Canc Res & Clin Trials Ctr, Dept Optimal Therapy, Hanoi, Vietnam
[13] CEON Ctr Especializado Oncol, Dept Oncol, Ribeirao Preto, Brazil
[14] Kanagawa Canc Ctr, Dept Gastroenterol, Tokyo, Japan
[15] China Med Univ & Hosp, Dept Surg, Taichung, Taiwan
[16] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[17] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[18] AstraZeneca, Global Med Affairs, Gaithersburg, MD USA
[19] AstraZeneca, Oncol R&D, Late Stage Dev, Gaithersburg, MD USA
[20] AstraZeneca, Stat, Gaithersburg, MD USA
[21] Cornell Univ, Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[22] Cornell Univ, Weill Med Coll, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.151
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1270
引用
收藏
页码：S1451 / S1452
页数：3
相关论文
共 50 条
  • [31] T-cell receptor pharmacodynamics associated with survival and response to tremelimumab (T) in combination with durvalumab (D) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).
    McCoon, Patricia
    Lee, Young S.
    Kelley, Robin Kate
    Guthrie, Violeta Beleva
    Wu, Song
    Bien, Stephanie A.
    Negro, Alejandra
    He, Philip
    Kurland, John
    Barrett, J. Carl
    Pilataxi, Fernanda
    Ching, Steven
    Abou-Alfa, Ghassan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Exploratory analysis of overall survival (OS) in the prospective, observational REFINE study
    Finn, Richard S.
    Kudo, Masatoshi
    Klumpen, Heinz-Josef
    Lim, Ho Yeong
    Merle, Philippe
    Ikeda, Masafumi
    Masi, Gianluca
    Frenette, Catherine T.
    Kim, Yoon Jun
    Gerolami, Rene
    Kurosaki, Masayuki
    Numata, Kazushi
    Pisarenko, Julia
    Ozgurdal, Kirhan
    Qin, Shukui
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [33] A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study.
    Abou-Alfa, Ghassan K.
    Chan, Stephen Lam
    Furuse, Junji
    Galle, Peter R.
    Kelley, Robin Kate
    Qin, Shukui
    Armstrong, Jon
    Darilay, Annie
    Vlahovic, Gordana
    Negro, Alejandra
    Sangro, Bruno
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [34] CASPIAN: OS results from a randomised Phase III study of first-line Durvalumab ± Tremelimumab plus chemotherapy in ED-SCLC: OS-Ergebnisse von CASPIAN, einer randomisierten Phase-III-Studie zur Erstlinientherapie von Durvalumab ± Tremelimumab
    Reinmuth, N.
    Paz-Ares, L.
    Chen, Y.
    Hotta, K.
    Trukhin, D.
    Statsenko, G.
    Hochmair, M. J.
    Ozguroglu, M.
    Li, Ho J.
    Voitko, O.
    Poltoratskiy, A.
    Ponce, S.
    Verderame, F.
    Havel, L.
    Bondarenko, I
    Kazarnowicz, A.
    Losonczy, G.
    Conev, N., V
    Armstrong, J.
    Byrne, N.
    Shire, N.
    Jiang, H.
    Goldman, J.
    Alt, J.
    PNEUMOLOGIE, 2020, 74 : S126 - S127
  • [35] Overall survival (OS) benefit with sipuleucel-T by baseline PSA: An exploratory analysis from the phase III IMPACT trial
    Chodak, Gerald
    Schellhammer, Paul F.
    Whitmore, James Boyd
    Sims, Robert Brownell
    Kantoff, Philip W.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial
    Peters, Solange
    Cho, Byoung Chul
    V. Luft, Alexander
    Alatorre-Alexander, Jorge
    Geater, Sarayut Lucien
    Laktionov, Konstantin
    Trukhin, Dmytro
    Kim, Sang-We
    Ursol, Grygorii M.
    Hussein, Maen
    Lim, Farah Louise
    Yang, Cheng-Ta
    Araujo, Luiz Henrique
    Saito, Haruhiro
    Reinmuth, Niels
    Lowery, Caitlin
    Mann, Helen
    Stewart, Ross
    Jiang, Haiyi
    Garon, Edward B.
    Mok, Tony
    Johnson, Melissa L.
    JOURNAL OF THORACIC ONCOLOGY, 2025, 20 (01) : 76 - 93
  • [37] Outcomes by baseline liver function in EMERALD-1: A phase III, randomised, placebo (PBO)-controlled study of durvalumab (D) with or without bevacizumab (B) with transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible unresectable hepatocellular carcinoma (uHCC)
    Chan, S. L.
    Decaens, T.
    Kudo, M.
    Erinjeri, J. P.
    Lencioni, R.
    Bouattour, M.
    Breder, V. V.
    Heo, J.
    Mazzaferro, V.
    Park, J-W.
    Alavez, A. Molina
    Kee, K. M.
    Xu, A.
    Inaba, Y.
    Dayyani, F.
    Zotkiewicz, M.
    McCoy, C. L.
    Makowsky, M.
    Sangro, B.
    ANNALS OF ONCOLOGY, 2024, 35 : S74 - S75
  • [38] Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600-mutant unresectable or metastatic melanoma (MM).
    Long, Georgina V.
    Eroglu, Zeynep
    Infante, Jeffrey R.
    Patel, Sapna Pradyuman
    Daud, Adil
    Johnson, Douglas Buckner
    Gonzalez, Rene
    Kefford, Richard
    Hamid, Omid
    Schuchter, Lynn Mara
    Cebon, Jonathan S.
    Sharfman, William Howard
    McWilliams, Robert R.
    Sznol, Mario
    Weber, Jeffrey S.
    Mookerjee, Bijoyesh
    Gasal, Eduard
    Redhu, Suman
    Flaherty, Keith T.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [39] Impact of baseline tumour burden on outcomes in EMERALD-1: A phase III study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in embolisation-eligible unresectable hepatocellular carcinoma (uHCC)
    Kudo, M.
    Lencioni, R.
    Erinjeri, J.
    Chan, S. L.
    Qin, S.
    Ren, Z.
    Arai, Y.
    Heo, J.
    Breder, V. V.
    Bouattour, M.
    Dayyani, F.
    Yoon, J-H.
    Chiu, C-F.
    Suttichaimongkol, T.
    Decaens, T.
    Griffin, R.
    Morgan, C.
    Ali, S. K.
    Balaji, K.
    Sangro, B.
    ANNALS OF ONCOLOGY, 2024, 35 : S1480 - S1480
  • [40] Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): Five-year (yr) overall survival (OS) data from a phase II trial
    Motzer, R. J.
    Rouge, T. de La Motte
    Harzstark, A. L.
    Michaelson, M. D.
    Liu, G.
    Gruenwald, V.
    Ingrosso, A.
    Tortorici, M. A.
    Bycott, P. W.
    Kim, S.
    Rini, B. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345